FDA issues nonapprovable letter to Schering-Plough/Merck

04/27/2008 | Yahoo!

The FDA has rejected an application by Schering-Plough/Merck Pharmaceuticals -- a joint venture of Schering-Plough Corp. and Merck & Co. -- to manufacture an allergy treatment that combines the active ingredients of their Claritin and Singulair tablets. The company said it is reviewing the agency's decision but declined to give more details.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY